|
03 Nov 2023 |
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023
|
|
02 Nov 2023 |
Fresenius Kabi launches Tyenne*, the first approved tocilizumab biosimilar in the European Union
|
|
02 Nov 2023 |
Kodiak Sciences announces first time presentation of primary endpoint data from tarcocimab tedromer phase 3 GLOW study in patients with diabetic retinopathy at American Academy of Ophthalmology annual meeting
|
|
02 Nov 2023 |
KEYTRUDA® (pembrolizumab) Significantly Improved Overall Survival (OS) Versus Placebo as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Nephrectomy
|
|
02 Nov 2023 |
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
|
|
01 Nov 2023 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Gemcitabine and Cisplatin as Treatment for Patients With Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
|
|
01 Nov 2023 |
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
|
|
01 Nov 2023 |
FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
|
|
01 Nov 2023 |
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056
|
|
31 Oct 2023 |
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
|
|
31 Oct 2023 |
Immunitas Therapeutics Presents Data for Novel Anti CLEC2D-TLR9 Conjugate Program at the Society for Immunotherapy of Cancer 2023 Annual Meeting
|
|
30 Oct 2023 |
SparX Biopharmaceutical Announces FDA Greenlight for IND Application of SPX-303, A First-In-Human anti-LILRB2/PD-L1 Antibody Drug
|
|
30 Oct 2023 |
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
|
|
30 Oct 2023 |
NovelMed Commences Phase II Trial for Anti-Bb Antibody (NM8074) in Treatment-Naïve PNH Patients: A Glimpse into the PNH Study Progress
|
|
30 Oct 2023 |
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
|
|
30 Oct 2023 |
JCR Pharmaceuticals Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA
|
|
30 Oct 2023 |
Merck KGaA, Darmstadt, Germany, Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
|
|
28 Oct 2023 |
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
|
|
27 Oct 2023 |
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
|
|
27 Oct 2023 |
ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
|
|
27 Oct 2023 |
Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
|
|
27 Oct 2023 |
FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
|
|
26 Oct 2023 |
First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in Europe
|
|
26 Oct 2023 |
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
|
|
25 Oct 2023 |
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers
|
